Granules India Inaugurates Two Centres of Excellence at IIT Hyderabad to Boost R&D
On December 1, 2025, Granules India Limited announced the launch of two advanced Centres of Excellence at the Technology Research Park of the Indian Institute of Technology (IIT) Hyderabad. This initiative aims to enhance research and development (R&D) capabilities in the pharmaceutical sector, particularly focusing on peptide development and particle engineering.
Overview of the Centres of Excellence
The two newly inaugurated centres are:
- Ascelis Center of Excellence for Peptide Development and Characterization
- Granules Center of Excellence for Particle Engineering
Ascelis Center of Excellence for Peptide Development and Characterization
This centre has been established under Ascelis Peptides, the Contract Development and Manufacturing Organization (CDMO) division of Granules India. It represents the company’s first peptide development and characterization facility in India.
The Ascelis Centre will focus on:
- Developing cosmetic peptides
- Therapeutic peptides
- Pharmaceutical peptides
Equipped to perform primary, secondary, and tertiary structure characterization, this facility enhances the scientific and technical capabilities of Granules India. The centre will collaborate closely with Senn Chemicals, the Swiss-based R&D unit of Granules, thereby strengthening the company’s global peptide development platform. This collaboration aims to reduce reliance on external partners by bringing advanced analytical and process development capabilities in-house.
Granules Center of Excellence for Particle Engineering
The Granules Center of Excellence for Particle Engineering is designed to advance research in several critical areas:
- Polymorph science
- Material science
- Advanced drug delivery systems, including amorphous solid dispersions
This centre replaces previous external or ad hoc development approaches with a dedicated research environment. It aims to support first-to-file opportunities, improve formulation performance, and create proprietary technologies tailored for regulated international markets.
Statements from Leadership
During the inauguration ceremony, Dr. Krishna Prasad Chigurupati, Chairman and Managing Director of Granules India, expressed his vision for the new centres. He stated, “Scientific excellence has always guided the long-term strategy of Granules India.” He emphasized that these Centres of Excellence would significantly strengthen the company’s capabilities in both peptides and advanced material sciences.
Dr. Chigurupati further noted that the new facilities would support the company’s CDMO ambitions by accelerating breakthrough development and fostering differentiated technologies that enhance global competitiveness. The ultimate goal is to deliver meaningful value to global partners and patients through deeper innovation and specialized infrastructure.
Impact on Granules India’s Market Position
Following the announcement of the Centres of Excellence, Granules India Limited’s share price saw a positive response, trading with a 1.37% gain as of 12:37 PM on the same day. This reflects investor confidence in the company’s strategic direction and commitment to enhancing its R&D capabilities.
Future Prospects
The establishment of these centres marks a significant milestone for Granules India as it seeks to position itself as a leader in the pharmaceutical industry. By investing in advanced research facilities, the company aims to drive innovation and improve the quality of its product offerings.
As the pharmaceutical landscape continues to evolve, Granules India’s focus on peptide development and particle engineering is likely to yield substantial benefits. These advancements will not only enhance the company’s product pipeline but also contribute to the overall growth of the pharmaceutical sector in India.
Conclusion
The inauguration of the Ascelis Center of Excellence for Peptide Development and Characterization and the Granules Center of Excellence for Particle Engineering at IIT Hyderabad is a strategic move by Granules India to bolster its R&D capabilities. This initiative is expected to foster innovation, improve product development processes, and enhance the company’s competitive edge in the global pharmaceutical market.
Note: This article is based on information available as of December 1, 2025, and may be subject to change as new developments occur.
